To provide a reference for managing congenital toxoplasmosis in China with limited drug accessibility.
Approach:
Case Presentation: A male infant born at 36⁺⁶ weeks was diagnosed with congenital toxoplasmosis confirmed by serological screening and cerebrospinal fluid NGS. Initial treatment with azithromycin was followed by a transition to pyrimethamine and sulfadiazine after obtaining informed consent from the family.
Key Findings:
The infant was diagnosed with mildly symptomatic congenital toxoplasmosis confirmed by serological screening.
Initial treatment with azithromycin was necessary due to limited drug access.
Standard therapy with pyrimethamine and sulfadiazine was successfully implemented after obtaining medications through family sourcing.
Interpretation:
This case illustrates the feasibility of implementing standard treatment regimens for congenital toxoplasmosis in settings with drug accessibility challenges.
Limitations:
Limited clinical experience with the standard regimen in China.
The case study is based on a single patient, which may limit generalizability.
Conclusion:
The management of congenital toxoplasmosis in this case serves as a reference for similar cases in China.
Updated 2025-2026 vaccination was linked to added protection in a CDC-funded analysis that became part of a broader debate over routine vaccine monitoring.
